Sign In
Buy IRTC
$117.17
-1.91 (-1.60%)
At Close: Jul 31, 2026
iRhythm Technologies, Inc. (IRTC) Q3 2024 Earnings Call Transcript
08:26pm, Wednesday, 30'th Oct 2024
iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q3 2024 Results Conference Call October 30, 2024 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, Investor Relations Quentin Blackford - Presi
IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates
07:36pm, Wednesday, 30'th Oct 2024
IRhythm Technologies (IRTC) came out with a quarterly loss of $1.26 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.89 per share a year ago.
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
05:15pm, Wednesday, 30'th Oct 2024
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients
iRhythm Technologies Announces Third Quarter 2024 Financial Results
04:08pm, Wednesday, 30'th Oct 2024
SAN FRANCISCO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prev
SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health company focused on creating trusted solutions that detect, predict, and prevent dise
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?
08:50am, Wednesday, 23'rd Oct 2024
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
01:18pm, Tuesday, 22'nd Oct 2024
On Monday, the FDA approved iRhythm Technologies, Inc.'s IRTC 510(k) submission related to prior design changes to the Zio AT device via letter to file.
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
12:41pm, Tuesday, 22'nd Oct 2024
IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.
iRhythm Technologies Receives FDA 510(k) Clearance for Design Updates Previously Made to Its Zio® AT Device
04:05pm, Monday, 21'st Oct 2024
Zio AT device, along with the Zio ECG Utilization Software (ZEUS) (K222389), enables the provision of ambulatory Mobile Cardiac Telemetry (MCT) monitoring service for non-critical care patients Zio AT
iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024
04:05pm, Wednesday, 16'th Oct 2024
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict
PHILADELPHIA, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating iRhythm Technologies, Inc. (NASDAQ: IRTC) (“iRhythm”) on behalf of the company's long-term share
iRhythm's Zio ECG System Gets Approval in Japan, Stock Falls
11:55am, Friday, 13'th Sep 2024
IRTC's Zio ECG monitoring system gets approval in Japan, marking a significant step in revolutionizing arrhythmia diagnostics with AI-powered technology.
SAN FRANCISCO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and preven
iRhythm Stock Gains Following Favorable Zio Monitor Study Data
01:14pm, Tuesday, 10'th Sep 2024
IRTC announces initial findings demonstrating the superior real-world performance of the next-generation Zio LTCM Monitor at the HRX 2024 meeting.
iRhythm Stock May Gain on Its Latest Deal With BioIntelliSense
12:01pm, Monday, 09'th Sep 2024
IRTC announces an exclusive license agreement with BioIntelliSense to develop and commercialize certain patented technology assets within AMC.
